Namazi Hospital is a hospital in Namazi Square, Shiraz, Iran. It was founded by Mohammad Namazi in 1950. Mohammad Namazi founded this hospital with 22 residential villas for physicians in 1950. It was later extended in 1975 and a polyclinic building, a six-storey parking and some affiliated buildings were constructed.

During the past decade, Namazi Hospital conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 3 clinical trials were completed, i.e. on average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Namazi Hospital" are "Congenital Fibrinogen Deficiency" (2 trials), "Afibrinogenemia" (1 trials), "Embolic Stroke" (1 trials), "End Stage Renal Disease" (1 trials) and "HER2-positive Breast Cancer" (1 trials). Many other conditions were trialed in "Namazi Hospital" in a lesser frequency.

Most popular intervention types in "Namazi Hospital" are "Drug" (4 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Octafibrin" (2 trials), "Bevacizumab + FOLFIRI-3" (1 trials), "Carboplatin" (1 trials), "Docetaxel" (1 trials) and "Enoxaparin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Namazi Hospital" are 6 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Namazi Hospital". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Namazi Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Namazi Hospital, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".